Diabetic Macular Edema Market to Exhibit Moderate Growth Rate till 2032, Investigates DelveInsight

DelveInsight's "Diabetic Macular Edema Market Insights, Epidemiology, and Market Forecast 2032" report delivers an in-depth understanding of the disease, historical and forecasted epidemiology as well as the Diabetic Macular Edema Market Size and Share in the 7MM (i.e. the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan).

The Diabetic Macular Edema market report covers emerging drugs, current treatment practices, market share of the individual therapies, current and forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.

Download a sample copy of the report @ https://www.delveinsight.com/sample-request/diabetic-macular-edema-dme-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Diabetic Macular Edema: An Overview
Diabetic Macular Edema (DME) is triggered by diabetic retinopathy (DR), a well-known complication of diabetes. DR is the most prevalent diabetic eye disease and the leading cause of irreversible blindness in people in their working years in the developed and other developing countries. Common signs and symptoms include dark spots like a smudge on glasses or gaps that may appear in the vision, blurred vision, double vision, colors can fade, or the affected person may find bright light or glare difficult.

Key highlights of the Diabetic Macular Edema Market Report
• In 2021, the total prevalent cases of DME were the highest in the US, with more than 1 million cases, and lowest in France with 60,000 cases.
• According to DelveInsight's analysis, DME is more prevalent in males as compared to females. DelveInsight's epidemiology model for DME estimates that in 7MM, approximately 0.5 million cases were of males, and 0.36 million cases were of females in 2021.
• In the 7MM, the total treated cases of DME in first-line were 0.44 million cases in 2021. As per the analysis, these cases are expected to reach 0.52 million cases by 2032. As per the analysis, approximately 0.11 million patients progressed from first-line to second-line and above and are expected to increase by 2032.

Diabetic Macular Edema Epidemiology Insights
Diabetic Macular Edema (DME) is triggered by diabetic retinopathy (DR), a well-known complication of diabetes. DR, which normally affects both eyes, is the most prevalent diabetic eye disease and the leading cause of irreversible blindness in people in their working years in the United States. People with type 1 or type 2 diabetes can develop DME. In people with DR, DME is the most common cause of vision loss.

Diabetic Macular Edema Epidemiology Segmentation in the 7MM
• Total Prevalent Cases
• Age-specific Diagnosed Cases
• Total Diagnosed Cases
• Gender-specific cases
• Treated cases
• Subgroup-specific Diagnosed Cases

Discover more information about the report @ https://www.delveinsight.com/sample-request/diabetic-macular-edema-dme-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Diabetic Macular Edema Treatment Market

Treatment of DME mainly involves the usage of anti-VEGF Drugs, corticosteroids, and Laser photocoagulation. Nonsteroidal anti-inflammatory drugs (NSAIDs), in the form of eye drops, are sometimes used either before or after cataract surgery to prevent the development of macular edema. Currently, intravitreal anti-VEGF agents are the preferred first-line treatment for DME. The three most used anti-VEGF drugs are Avastin, Eylea, and Lucentis. These drugs block the activity of VEGF and slow the progress of macular edema. Corticosteroids are mostly a second-line treatment option. These anti-inflammatory drugs are usually administered via eye drops, implants, or injections of sustained-release corticosteroids into or around the eye. US FDA approved sustained-release corticosteroid implants for more serious or longer-lasting conditions are Ozurdex, Retisert, and Iluvien.

Diabetic Macular Edema Market Size
The market size is expected to increase during the forecast period (2019‒2032), owing to the launch of upcoming therapies. The United States is the largest market with an estimated size of around USD 1.7 billion in 2021. The market size of Diabetic Macular Edema (DME) in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan was found to be ~USD 2.9 billion in 2021.

Diabetic Macular Edema Market Insights
DelveInsight's analysts estimate that the market is expected to show positive growth, mainly attributed to increase in diabetic population, rise in number of healthcare expenditure, and change in lifestyle (2019-2032). Corticosteroid implants are usually used as a second-line treatment for patients without significant response to anti-VEGF injections. Corticosteroids provide an alternative therapeutic approach, especially in patients with DME who are immune to anti-VEGF therapy. They not only block various chemokines and inflammatory cytokines, but also interact with other pro-inflammatory molecules such as VEGF-A, reducing vascular permeability and preventing angiogenesis.

Read more about the report @ https://www.delveinsight.com/report-store/diabetic-macular-edema-dme-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Content
1. Key Insights
2. Report Introduction
3. Diabetic Macular Edema Market Overview at a Glance
4. Executive Summary of Diabetic Macular Edema
5. Epidemiology and Market Forecast Flow
6. Disease Background and Overview
7. Current Treatment
8. Epidemiology and Patient Population
10. Key Endpoints in Diabetic Macular Edema
11. Marketed Therapies
12. Emerging Therapies
13. Conjoint Analysis of DME Therapies
14. Diabetic Macular Edema: Seven Major Market Analysis
15. Market Access and Reimbursement
16. Market Drivers
17. Market Barriers
18. SWOT Analysis
19. Unmet Needs
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
23. About DelveInsight

Connect with our Business Process Expert @ https://www.delveinsight.com/report-store/diabetic-macular-edema-dme-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Contact
Yash Bhardwaj
info@delveinsight.com

About Us
Delveinsight is a business consulting and market research company, providing expert business solutions for life science vertical and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

This release was published on openPR.